Synta

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company based in Pennsylvania, dedicated to developing innovative therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with a high unmet medical need. Their lead clinical candidate, resmetirom, is currently undergoing studies for the treatment of patients with NASH and significant liver fibrosis.

With a focus on improving care for patients with NASH, Madrigal Pharmaceuticals aims to address the lack of FDA-approved treatments for this condition. Their commitment to advancing novel therapeutics for NASH underscores their dedication to making a meaningful impact on the lives of those affected by this challenging liver disease.

Generated from the website